Abstract:Immunotherapies that target PD-1/PD-L1 axis have shown unprecedented success in awide variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells upon T cell activation. After engagement with its ligands, mainly PD-L1, PD-1 is activated and recruits the phosphatase SHP-2 in proximity to T cell receptor (TCR) and CD28 signaling. This event results in dephosphorylation and attenuation of key molecules in TCR and CD28 pathway, leading to inhibition of T cell proliferation, activation, cytokine production, altered metabolism and cytotoxic T lymphocytes (CTLs) killer functions, and eventual death of activated T cells. Bodies evolve coinhibitory pathways controllingTcell response magnitude and duration to limit tissue damage and maintain self-tolerance. However, tumor cells hijack these inhibitory pathways to escape host immune surveillance by overexpression of PD-L1. This provides the scientific rationale for clinical application of immune checkpoint inhibitors in oncology. The aberrantly high expression of PD-L1 in tumor microenvironment (TME) can be attributable to the "primary" activation of multiple oncogenic signaling and the "secondary" induction by inflammatory factors such as IFN-.. Clinically, antibodies targeting PD-1/PD-L1 reinvigorate the "exhausted" T cells in TME and show remarkable objective response and durable remission with acceptable toxicity profile in large numbers of tumors such as melanoma, lymphoma, and mismatch-repair deficient tumors. Nevertheless, most patients are still refractory to anti-PD-1/PD-L1 therapy. Identifying the predictive biomarkers and design rational PD-1-based combination therapy become the priorities in cancer immunotherapy. PD-L1 expression, cytotoxic T lymphocytes infiltration, and tumor mutation burden (TMB) are generally considered as the most important factors affecting the effectiveness of PD-1/PD-L1 blockade. The revolution in cancer immunotherapy achieved by PD-1/PD-L1 blockade offers the paradigm for scientific translation from bench to bedside. The next decades will without doubt witness the renaissance of immunotherapy.

Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives

Further knowledge and developments in resistance mechanisms to immune checkpoint inhibitors

Addressing the Challenges of PD-1 Targeted Immunotherapy in Cancer Treatment

PD-1/PD-L1 Immunotherapy: Combating Drug Resistance in Breast Cancer

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PDL1 blockade

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade

Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance

Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy

Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy

Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape

Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics

Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment

Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.

Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy

Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook

Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors

Cancer Immunotherapy: An Overview on Small Molecules as Inhibitors of the Immune Checkpoint PD-1/PD-L1 (2015-2021).

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms